Understanding the genotype of follicular thyroid tumors

Endocrine Pathology

Volumn 16, Issue 4, 2005, Pages 311-321

  Hunt, Jennifer ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Molecular Anatomic Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MOLECULAR MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; TRANSCRIPTION FACTOR PAX8;

CONFERENCE PAPER; GENE ACTIVATION; GENE TRANSLOCATION; GENOTYPE; GOLD STANDARD; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; ONCOGENE; PAPILLARY CARCINOMA; PATHOLOGIST; POINT MUTATION; PRIORITY JOURNAL; SUPPRESSOR GENE; THYROID FOLLICULAR CARCINOMA; GENETICS; MUTATION; REVIEW; THYROID TUMOR;

CARCINOMA, PAPILLARY, FOLLICULAR; GENOTYPE; HUMANS; MUTATION; THYROID NEOPLASMS;

EID: 33646683552     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:16:4:311     Document Type: Conference Paper

References (67)

1. Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metabol 86:2187-2190, 2001.
2. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metabol 88:5399-5404, 2003.
3. Hunt JL, Livolsi VA, Baloch ZW, et al. A novel microdissection and genotyping of follicular-derived thyroid tumors to predict aggressiveness. Hum Path 34:375-380, 2003.
4. Tallini G, Ghossein RA, Emanuel J, et al. Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. J Clin Oncol 16:1158-1166, 1998.
5. Oxford G, Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 189:117-128, 2002.
6. Mizutani S, Inouye K, Koide H, Kaziro Y. Involvement of B-Raf in Ras-induced Raf-1 activation. FEBS Lett 507:295-298, 2001.
7. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689, 1989.
8. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metabol 71:223-229, 1990.
9. Garcia-Rostan G, Zhao H, Camp RL, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226-3235, 2003.
10. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metabol 88:2745-2752, 2003.
11. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis. Trends Cell Biol 14:639-647, 2004.
12. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nature Rev Molecul Cell Biol 5:875-885, 2004.
13. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metabol 88:2318-2326, 2003.
14. Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159-164, 1989.
15. Capella G, Matias-Guiu X, Ampudia X, de Leiva A, Perucho M, Prat J. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction- fragment-length polymorphism analysis from paraffin-embedded tissues. Diag Mol Pathol 5:45-52, 1996.
16. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457, 2003.
17. Wan PT, Garnett MJ, Roe SM, et al. Cancer genome P, mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF [see comment]. Cell 116:855-867, 2004.
18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer [see comment]. Nature 417:949-954, 2002.
19. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202:247-251, 2004.
20. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metabol 89: 2414-2420, 2004.
21. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627, 2003.
22. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457, 2003.
23. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22:6455-6457, 2003.
24. Fusco A, Viglietto G, Santoro M. A new mechanism of BRAF activation in human thyroid papillary carcinomas [comment]. J Clin Invest 115:20-23, 2005.
25. Salvatore G, Chiappetta G, Nikiforov YE, et al. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. Eur J Cancer 41:816-821, 2005.
26. Xing M, Vasko V, Tallini G, et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metabol 89:1365-1368, 2004.
27. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metabol 89:2867-2872, 2004.
28. Nikiforova MN, Ciampi R, Salvatore G, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209:1-6, 2004.
29. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer [see comment]. J Clin Invest 115:94-101, 2005.
30. Aman P. Fusion genes in solid tumors. Sem Cancer Biol 9:303-318, 1999.
31. Marques AR, Espadinha C, Frias MJ, et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer 91:732-738, 2004.
32. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016-1023, 2002.
33. Gustafson KS, LiVolsi VA, Furth EE, Pasha TL, Putt ME, Baloch ZW. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies. Am J Clin Pathol 120:175-181, 2003.
34. Dwight T, Thoppe SR, Foukakis T, et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metabol 88:4440-4445, 2003.
35. Cheung L, Messina M, Gill A, et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metabol 88:354-357, 2003.
36. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-77, 2003.
37. Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metabol 87:3947-3952, 2002.
38. French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 162:1053-1060, 2003.
39. Lui WO, Foukakis T, Liden J, et al. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARgamma fusion oncogene. Oncogene 29:1-10, 2005.
40. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anato Pathol 8:345-354, 2001.
41. Nikiforova MN, Caudill CM, Biddinger P, Nikiforov YE. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol 10:15-22, 2002.
42. Klugbauer S, Pfeiffer P, Gassenhuber H, Beimfohr C, Rabes HM. RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics 73:149-160, 2001.
43. Sheils OM, O'Leary JJ, Uhlmann V, Luttich K, Sweeney EC. ret/PTC-1 activation in Hashimoto's thyroiditis. Int J Surg Pathol 8:185-189, 2001.
44. Wirtschafter A, Schmidt R, Rosen D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 107:95-100, 1997.
45. Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6:1093-1103, 2000.
46. Thomas GA, Bunnell H, Cook HA, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metabol 84:4232-4238, 1999.
47. Santoro M, Thomas GA, Vecchio G, et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer 82:315-322, 2000.
48. Fischer AH, Bond JA, Taysavang P, Battles OE, Wynford-Thomas D. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol 153:1443-1450, 1998.
49. Motomura T, Nikiforov YE, Namba H, et al. ret rearrangements in Japanese pediatric and adult papillary thyroid cancers. Thyroid 8:485-489, 1998.
50. Chung JH, Hahm JR, Min YK, et al. Detection of RET/PTC oncogene rearrangements in Korean papillary thyroid carcinomas. Thyroid 9:1237-1243, 1999.
51. Fusco A, Chiappetta G, Hui P, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 160:2157-2167, 2002.
52. Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287-294, 1998.
53. Papotti M, Volante M, Giuliano A, et al. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am J Surg Pathol 24:1615-1621, 2000.
54. Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am J Surg Pathol 24:1622-1626, 2000.
55. Sheils OM, O'Leary JJ, Sweeney EC. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR. J Pathol 192:32-36, 2000.
56. Hunt JL, LiVolsi VA, Baloch ZW, et al. Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile. Am J Surg Pathol 27:159-166, 2003.
57. Sheikh HA, Tometsko M, Niehouse L, et al. Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence. Am J Surg Pathol 28:101-106, 2004.
58. Hunt JL, Fowler M, Lomago D, et al. Tumor suppressor gene allelic loss profiles of the variants of papillary thyroid carcinoma. Diag Mol Pathol 13:41-46, 2004.
59. Tung WS, Shevlin DW, Kaleem Z, et al. Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes Cancer 19:43-51, 1997.
60. Trovato M, Fraggetta F, Villari D, et al. Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. J Clin Endocrinol Metabol 84:3235-3240, 1999.
61. Ward LS, Brenta G, Medvedovic M, Fagin JA. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metabol 83:525-530, 1998.
62. Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 27:1559-1564, 2003.
63. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66:321-330, 1990.
64. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83:135-158, 1985.
65. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573, 1997.
66. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 27:244-251, 2000.
67. Wreesmann VB, Ghossein RA, Patel SG, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 161:1549-1556, 2002.